A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment.

Donor lymphocyte infusion (DLI) is used to prevent or treat haematological malignancies relapse after allogeneic stem cell transplantation (allo-SCT). Recombinant human granulocyte colony-stimulated factor primed DLI (gDLI) is derived from frozen aliquots of the peripheral blood stem cell collection. We compared the efficacy and safety of gDLI and classical DLI after allo-SCT. We excluded haploidentical allo-SCT. Initial diseases were acute myeloblastic leukaemia ( = 45), myeloma ( = 38), acute lymphoblastic leukaemia ( = 20), non-Hodgkin lymphoma ( = 10), myelodysplasia ( = 8), Hodgkin lymphoma ( = 8), chronic lymphocytic leukaemia ( = 7), chronic myeloid leukaemia ( = 2) and osteomyelofibrosis ( = 1). Indications for DLI were relapse ( = 96) or pre-emptive treatment ( = 43). Sixty-eight patients had classical DLI and 71 had gDLI. The response rate was 38.2%, the 5-year progression-free survival (PFS) rate was 38% (29-48) and the 5-year overall survival (OS) rate was 37% (29-47). Graft versus host disease rate was 46.7% and 10.1% of patients died from toxicity. There were no differences between classical DLI and gDLI in terms of response ( = 0.28), 5-year PFS ( = 0.90), 5-year OS (. 0.50), GvHD ( = 0.86), treated GvHD ( = 0.81) and cause of mortality (. 0.14). In conclusion, this study points out no major effectiveness or toxicity of gDLI compared to classical DLI.